Additive Manufacturer Green Trade Association Announces New Members
27.7.2021 14:59:00 EEST | Business Wire | Press release
The Additive Manufacturer Green Trade Association (AMGTA), a global trade organization created to promote the environmental benefits of additive manufacturing (AM), announced today that eight additional leading AM companies have joined the trade group to advance sustainability in AM, bringing its membership ranks to 28 members.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005192/en/
Joining the AMGTA as a new Founding Member is Stratasys, a global leader in polymer 3D printing solutions for industries such as aerospace, automotive, consumer products, and healthcare. Stratasys will serve alongside existing Founding Members ExOne, the pioneer and global leader in industrial 3D printing systems using binder jet 3D printing technology; QC Laboratories, an advanced non-destructive testing laboratory focused on AM components; Sintavia, a designer and 3D printer of a new generation of flight and launch components; and Taiyo Nippon Sanso Corporation (one of the operating companies under Nippon Sanso Holdings Corporation), a supplier of stable industrial gases to a wide variety of global industries. These five Founding Members will determine the strategic direction of the AMGTA, provide governance oversight, and consider future research projects that members may vote to commission.
Joining the AMGTA as new Participating Members are: 3D Metalforge, a global AM company providing greater value to its customer through new and innovative additive manufacturing technologies; 3D Systems, the leader in enabling additive manufacturing solutions for applications in growing markets that demand high-reliability products; 3YOURMIND, an agile manufacturing software solutions provider dedicated to optimizing the additive manufacturing workflow; AMT, a global leader in automated chemical vapor smoothing (post-processing) systems for additively manufactured parts; Hyperion Metals, a Tennessee-focused company developing sustainable, zero carbon titanium metal powders for the growing additive manufacturing industry; NatureWorks, a world-leading biotechnology company using plants to turn greenhouse gases like CO2 into a biopolymer called Ingeo; and The Barnes Global Advisors, the world’s largest independent advanced manufacturing engineering consultancy.
These new Participating Members will serve alongside existing Participating Members AMEXCI, BASF 3D Printing Solutions, Danish AM Hub , DyeMansion, EOS, Fraunhofer Institute for Laser Technology (ILT), GE Additive, HP, Materialise, National Manufacturing Institute Scotland, Rusal America , Siemens Digital Industries Software, SLM Solutions, Stryker, TRUMPF, and 6K.
“I’m elated to welcome aboard our new Founding Member Stratasys, as well as each of our new Participating Member companies,” said Sherry Handel, Executive Director of the AMGTA. “Their collective pledge to support the AMGTA’s mission well-positions our trade group for accelerated growth and investment in new sustainability research projects in additive manufacturing. I look forward to working with each of our members as we expand the AMGTA as the key industry resource committed to advancing sustainability in the AM industry.”
About AMGTA. The AMGTA was launched in November 2019 to promote the environmental benefits of additive manufacturing (AM) over traditional methods of manufacturing. The AMGTA is a non-commercial, unaffiliated organization open to any additive manufacturer or industry stakeholder that meets certain criteria relating to sustainability of production or process.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005192/en/
Contact information
Sherry Handel
+1 954.308.0888
www.amgta.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom